# The EVERY Company

> The EVERY Company makes real egg proteins without raising chickens. Its microbes turn sugar into ovalbumin and other functional proteins, which food manufacturers use for binding, gelling, foaming, whipping and protein fortification. After years of premium demonstrations, the company has narrowed its commercial argument to a practical one: OvoPro is a shelf-stable, consistent B2B ingredient that can reduce exposure to avian flu, cold chains and volatile egg prices.

- **Founded:** 2014
- **Headquarters:** Daly City, United States
- **Founders:** Arturo Elizondo (Co-founder and CEO), David Anchel (Co-founder and founding scientist), Isha Datar (Co-founder through New Harvest)
- **Products:** OvoPro, OvoBoost, EVERY Egg, EVERY Pepsin, Application and formulation support
- **Notable:** Produced an early hen-free egg-white meringue during the 2014-2015 IndieBio period., Commercialized animal-free pepsin with Ingredion in 2020., Raised a $175 million Series C in 2021, bringing disclosed funding at that time to $233 million.

## Products & services

- **OvoPro** — A powdered ovalbumin ingredient, formerly EVERY EggWhite, that can partially or fully replace egg or egg-white functionality in baked goods, prepared foods, pasta, bars and other applications. It binds, gels, foams and whips and is shelf-stable for up to 24 months.
- **OvoBoost** — A highly soluble, neutral-tasting protein, formerly EVERY Protein, intended to fortify coffee, juice, soda, syrup and baked goods without the chalkiness associated with many protein additives.
- **EVERY Egg** — A liquid, animal-free whole-egg analogue demonstrated in omelets, custards and cocktails at Eleven Madison Park and later selected by Grupo Palacios for product development.
- **EVERY Pepsin** — An animal-free version of the protein-digesting enzyme, launched commercially with Ingredion as an early demonstration of the platform beyond egg proteins.
- **Application and formulation support** — B2B sampling, formulation and scale-up work that helps food manufacturers integrate fermentation-derived proteins into existing products and production lines.

## Achievements

- Produced an early hen-free egg-white meringue during the 2014-2015 IndieBio period.
- Commercialized animal-free pepsin with Ingredion in 2020.
- Raised a $175 million Series C in 2021, bringing disclosed funding at that time to $233 million.
- Received an FDA 'no questions' letter for GRAS Notice 1104 in October 2023 covering specified uses of its egg-white protein.
- Debuted EVERY Egg in a multicourse menu at three-Michelin-starred Eleven Madison Park in 2023.
- Received U.S. patent 12,096,784 covering recombinant ovalbumin applications in 2024, followed by European patent coverage.
- Won a $2 million U.S. Department of Defense award to assess domestic manufacturing in 2024.
- Raised a $55 million Series D in November 2025 to expand capacity and pursue profitability.
- Reached nationwide products sold through Walmart and Target-linked channels by 2026.
- Quadrupled contracted production capacity with Huvepharma in June 2026 after a reported 550% jump in annual order volume versus all of 2025.

## Latest updates

- **2026-06** — Expanded its Huvepharma/Biovet manufacturing agreement to quadruple OvoPro production capacity after annual orders booked in early 2026 reached 550% of total 2025 order volume.
- **2026-04** — Appointed Mario Patiño as its first chief revenue officer following nationwide retail exposure through products sold at Walmart and Target.
- **2026-03** — Announced Healthier Comforts' Animal-Free Egg White Protein Powder, the first consumer-sized OvoPro product for home cooking and baking.
- **2025-11** — Closed a $55 million Series D led by McWin Capital Partners to expand manufacturing, support a nationwide rollout and move toward profitability.
- **2025-03** — Earthbar introduced limited-time protein mocha and matcha lattes using an OvoBoost syrup across selected California locations.
- **2024-12** — Received a $2 million Department of Defense award for a U.S. manufacturing feasibility assessment and expanded recombinant ovalbumin patent coverage in Europe.

## Links

- Website: https://every.com/
- LinkedIn: https://www.linkedin.com/company/theeverycompany
- Twitter/X: https://x.com/theeverycompany
- Instagram: https://www.instagram.com/theeverycompany/
- Facebook: https://www.facebook.com/theEVERYcompany/

---

Profile page: https://yespress.io/every-company
Published by YesPress — https://yespress.io
Last updated: 2026-09-28